FDA wants to select the pathogens for drug developers to target in order to receive incentives for developing antibiotics to treat drug-resistant bacteria.
“Because antibiotic resistance evolves rapidly in this dynamic field” and many organisms are involved, CDER Director Janet Woodcock suggested to a House panel March 8 that Congress “set up some general criteria and then have FDA designate
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?